SER logo

SERINA THERAPEUTICS INC.

SERNYSE AMERICAN
🏆 #4648 by market capUS Equity
$157.93▼ $0.17 (−0.11%)
🌙 After hours$2.08▼ 98.68%Simulated price
🔔
Track SER
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 0.1%
7d▲ 6620.4%
14d▲ 6736.8%
30d▲ 6293.9%
ytd▲ 8390.9%
1y▲ 2996.7%
🏦Market Cap
$31M
Small Cap
📈Revenue Growth (YoY)
-100.0%
Declining
📊Gross Margin
0.0%
Thin
💵FCF Margin
0.0%
Thin
⚖️P/S Ratio
0.0x
Cheap
Otter Score
72
Fair

Trading Snapshot

Day Range
$157.43 – $158.89
52-Week Range
$1.22 – $5.83
Volume
$2.67B
Avg Volume
$3.55B
Shares Outstanding
15.0M
Next Earnings
Nov 11, 2026

Fundamentals Snapshot

Annual Revenue
$4M
Last Q Revenue
$841,381
P/E Ratio
-1.1
P/S Ratio
0.0x
EPS (TTM)
$-1.29
Dividend Yield
0.00%
Dilution (1yr)
−5.2%

Why Investors Own SER

  • ✓High-growth profile — revenue up +5.6% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 29% gross margin and 19% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SER logo

SERINA THERAPEUTICS INC.

SER
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▼ −100.0% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-246.4%▼ −353.7% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$24M▲ +40.9% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$18M▲ +4.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
10.2M▼ −5.2% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
−$86K▼ −$3M YoY
StockOtter · stockotter.space

About SERINA THERAPEUTICS INC.

Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Fair
72/100

Analyst Price Target

ⓘ
Average Target
$209.23
▲ +32.5% Upside
High Target$249.29
Low Target$181.64
Based on 22 analysts

Latest News & Updates

🚀
Reuters·2h ago

SERINA THERAPEUTICS INC. tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift SER price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Barron’s·1d ago

SERINA THERAPEUTICS INC. announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.